Baker Phillip, Kay Adrian, Walls Helen
Global Health. 2014 Sep 12;10:66. doi: 10.1186/s12992-014-0066-8.
Trade and investment liberalization (trade liberalization) can promote or harm health. Undoubtedly it has contributed, although unevenly, to Asia's social and economic development over recent decades with resultant gains in life expectancy and living standards. In the absence of public health protections, however, it is also a significant upstream driver of non-communicable diseases (NCDs) including cardiovascular disease, cancer and diabetes through facilitating increased consumption of the 'risk commodities' tobacco, alcohol and ultra-processed foods, and by constraining access to NCD medicines. In this paper we describe the NCD burden in Asian countries, trends in risk commodity consumption and the processes by which trade liberalization has occurred in the region and contributed to these trends. We further establish pressing questions for future research on strengthening regulatory capacity to address trade liberalization impacts on risk commodity consumption and health.
A semi-structured search of scholarly databases, institutional websites and internet sources for academic and grey literature. Data for descriptive statistics were sourced from Euromonitor International, the World Bank, the World Health Organization, and the World Trade Organization.
Consumption of tobacco, alcohol and ultra-processed foods was prevalent in the region and increasing in many countries. We find that trade liberalization can facilitate increased trade in goods, services and investments in ways that can promote risk commodity consumption, as well as constrain the available resources and capacities of governments to enact policies and programmes to mitigate such consumption. Intellectual property provisions of trade agreements may also constrain access to NCD medicines. Successive layers of the evolving global and regional trade regimes including structural adjustment, multilateral trade agreements, and preferential trade agreements have enabled transnational corporations that manufacture, market and distribute risk commodities to increasingly penetrate and promote consumption in Asian markets.
Trade liberalization is a significant driver of the NCD epidemic in Asia. Increased participation in trade agreements requires countries to strengthen regulatory capacity to ensure adequate protections for public health. How best to achieve this through multilateral, regional and unilateral actions is a pressing question for ongoing research.
贸易和投资自由化(贸易自由化)既可能促进健康,也可能损害健康。毫无疑问,近几十年来,它尽管程度不均,但对亚洲的社会和经济发展做出了贡献,带来了预期寿命和生活水平的提高。然而,在缺乏公共卫生保护的情况下,它也是包括心血管疾病、癌症和糖尿病在内的非传染性疾病(NCDs)的一个重要上游驱动因素,它通过促使人们更多地消费“风险商品”烟草、酒精和超加工食品,并限制人们获得非传染性疾病药物的机会来实现这一点。在本文中,我们描述了亚洲国家的非传染性疾病负担、风险商品消费趋势以及该地区贸易自由化发生的过程及其对这些趋势的影响。我们还提出了未来研究的紧迫问题,即如何加强监管能力,以应对贸易自由化对风险商品消费和健康的影响。
对半结构化搜索学术数据库、机构网站和互联网资源,以获取学术文献和灰色文献。描述性统计数据来自欧睿国际、世界银行、世界卫生组织和世界贸易组织。
烟草、酒精和超加工食品在该地区的消费很普遍,且在许多国家呈上升趋势。我们发现,贸易自由化可以通过促进商品、服务和投资贸易的方式,推动风险商品的消费,同时也会限制政府制定政策和计划以减轻此类消费的可用资源和能力。贸易协定中的知识产权条款也可能限制人们获得非传染性疾病药物的机会。不断演变的全球和区域贸易体系的 successive layers,包括结构调整、多边贸易协定和优惠贸易协定,使得生产、销售和分销风险商品的跨国公司能够越来越多地渗透并促进亚洲市场的消费。
贸易自由化是亚洲非传染性疾病流行的一个重要驱动因素。更多地参与贸易协定要求各国加强监管能力,以确保对公众健康提供充分保护。如何通过多边、区域和单边行动最好地实现这一点,是当前研究的一个紧迫问题。